Ranibizumab biosimilar (Oceva) – real-world experience from India (RORE study)

20251 citationsJournal Article

Authors

Ashish Sharma · Lotus Clinical Research

Jay Sheth · Aditya Jyot Eye Hospital

Chitaranjan Mishra · Electrovaya (Canada)

Debdulal Chakraborty · Eye Care Associates

Bhagyashree Meshram · Aditya Jyot Eye Hospital

Surendar S. Purohit · Electrovaya (Canada)

International Retina Biosimilar Study Group (Inter BIOS Group)

Abstract

The preliminary real-world data from this limited early series suggest that ranibizumab biosimilar (Oceva) appears to be efficacious and safe across the approved indications. However, long-term data with a larger population are needed to further strengthen the findings of this study.

Topics & Keywords

Publication Details

Published in: Expert Opinion on Biological Therapy

Volume 25, Issue 12, pp. 1353-1358

DOI: 10.1080/14712598.2025.2606897

Field-Weighted Citation Impact: 0.91

Command Palette

Ranibizumab biosimilar (Oceva) – real-world experience from India (RORE study)

Authors

Abstract

Topics & Keywords

Publication Details